Dr Sam Chamberlain is a Wellcome Trust Fellow and Honorary Consultant (Board Certified) Psychiatrist, at the University of Cambridge Department of Psychiatry, and Cambridge & Peterborough NHS Foundation Trust, and is a Visiting Researcher at BMH.
His research focuses on the neurobiology and treatment of addictive, impulsive, and compulsive disorders. He combines studies in people with mental disorders and longitudinal population cohorts to understand dimensional measures (intermediate phenotypes) that predispose to a range of mental health problems. For example, he showed that noradrenaline and serotonin, two key brain transmitters, play different roles in distinct aspects of impulsivity. He identified several vulnerability markers for obsessive-compulsive disorders – cognitive problems that run in families of people with these conditions. Dr Chamberlain, along with collaborators, identified a new treatment for gambling disorder, and demonstrated that this medication works partly by enhancing cognition and brain activation in patients.
Dr Chamberlain has obtained approximately $4.5 million (AUD equivalent) in research funding to date, and has published widely. He is co-author of several books including ‘Clinical Guide to Obsessive Compulsive and Related Disorders' and ‘Why Can't I Stop? Reclaiming Your Life from a Behavioral Addiction’.
Chamberlain, S. R., Blackwell, A. D., Fineberg, N. A., Robbins, T. W. et al. (2005). The neuropsychology of obsessive compulsive disorder: the importance of failures in cognitive and behavioural inhibition as candidate endophenotypic markers. Neuroscience & Biobehavioral Reviews, 29(3), 399-419.
Chamberlain, S. R., Fineberg, N. A., Blackwell, A. D., Robbins, T. W., & Sahakian, B. J. (2006). Motor inhibition and cognitive flexibility in obsessive-compulsive disorder and trichotillomania. American Journal of Psychiatry, 163(7), 1282-1284.
Chamberlain, S. R., Muller, U., Blackwell, A. D., Clark, L., et al. (2006). Neurochemical modulation of response inhibition and probabilistic learning in humans. Science, 311(5762), 861-863.
Chamberlain, S. R., Menzies, L., Hampshire, A., Suckling, J. et al. (2008). Orbitofrontal dysfunction in patients with obsessive-compulsive disorder and their unaffected relatives. Science, 321(5887), 421-422.
Chamberlain, S. R., Hampshire, A., Muller, U., Rubia, K. et al. (2009). Atomoxetine modulates right inferior frontal activation during inhibitory control: a pharmacological functional magnetic resonance imaging study. Biological Psychiatry, 65(7), 550-555.